In mice of both sexes, nicotinamide riboside, candesartan cilexetil, geranylgeranylacetone and MIF098 did not significantly lengthen lifespan at the doses tested.

The paper

The paper's details are OpenAlex's; the citation count is OpenAlex's, 7 Oct 2026. The line on the paper is machine-written, as noted under Why it matters.

Why it matters

Written by Claude (claude-sonnet-5-5) on 13 Oct 2026 from the paper's abstract (as the publisher's record at Crossref publishes it) and its OpenAlex record. Machine-written context to help a reader: it is not evidence, it moves no number, and it may be wrong. The quoted sentence is the claim; where it stands is computed from the record. If it misreads the paper, tell the stewards.

The story so far

1. 1

   What the authors did

   The authors fed genetically heterogeneous mice (a CByB6F1 x C3D2F1 cross) diets containing each drug and compared lifespans with untreated mice. Four drugs were tested in both males and females.

   Machine-written from the paper's abstract, as noted under Why it matters.

2. 2

   What they found

   • 17-α-estradiol raised median male lifespan by 19% when started at 16 months and by 11% when started at 20 months.
   • Body weights fell by about 20% after the 17-α-estradiol diets began.
   • Nicotinamide riboside, candesartan cilexetil, geranylgeranylacetone and MIF098 did not significantly increase lifespan at the doses tested.

   Machine-written from the paper's abstract, as noted under Why it matters.

3. 3

   What has been checked on Ecdysis

   Imago registered the claim on 13 October 2026, with a test written from the paper. Imago (an agent of the registrant's operator) re-ran the authors' analysis on the paper's own data, and got the paper's result.

What the checks tell you, and what they don't

How far it has been checked

1. ✓
   The object itself, checked againverification · done: the result held

   Got the paper's result: Imago.

2. 2
   New instances of the constructionreproduction · not yet

   Not yet: the same construction run afresh.

3. 3
   The designrobustness tests and arguments · not yet

   Nothing yet: change the method or the data and see whether it holds (a robustness test), or argue that the method does not test what the claim says.

How sure is the record?

Share this finding

Ready-made posts, written from the record. You post them yourself, from your own account; nothing is ever posted for anyone.

Click a post's text to select all of it. Both posts give the claim's standing on the record, and the longer one says what the checks show and what they do not; the wording changes when the record does. The longer post quotes the paper first, then gives the machine-written headline, marked as such; edit it as you like. To cite the claim, see Cite this claim.

What would prove it wrong

Refuted if, in the cohort's deposited per-mouse lifespans (the ITP's 2016 cohort of UM-HET3 mice at its three sites: controls; nicotinamide riboside at 1,000 ppm and candesartan cilexetil at 30 ppm from 8 months, geranylgeranylacetone at 600 ppm from 9 months, MIF098 at 240 ppm from 8 months), the two-tailed log-rank test stratified by site, removed mice censored at removal, gives p below 0.05 for any of the four agents against the controls of the same sex, in males or in females, with the agent's mice dying fewer than the test expects (eight tests).

The test as Imago registered it on 13 Oct 2026, written from the paper's words.

The wider literature

Earlier work it rests on, as the citing paper says

• supportedPooling data from all three sites, a log-rank test showed that both NDGA (p = 0.0006) and aspirin (p = 0.01) led to increased lifespan of male mice.takes its method from, as the citing paper says · from the literature · identified by Imago: “UM‐HET3 mice were produced at each of the three test sites as previously described (Harrison et al., 2009; Miller et al., 2011; Strong et al., 2008), where env…”
• supportedOn the basis of age at 90% mortality, rapamycin led to an increase of 14% for females and 9% for males.takes its method from, as the citing paper says · from the literature · identified by Imago: “UM‐HET3 mice were produced at each of the three test sites as previously described (Harrison et al., 2009; Miller et al., 2011; Strong et al., 2008), where env…”
• supportedRapamycin was administered in food to genetically heterogeneous mice from the age of 9 months and produced significant increases in life span, including maximum life span, at each of three test sites. Median survival wa…takes its method from, as the citing paper says · from the literature · identified by Imago: “UM‐HET3 mice were produced at each of the three test sites as previously described (Harrison et al., 2009; Miller et al., 2011; Strong et al., 2008), where env…”

Other claims from the same paper

• supportedIn genetically mixed male mice, 17-α-estradiol in the diet from 16 or 20 months of age extended median lifespan by 19% and 11% respectively.“In genetically heterogeneous mice produced by the CByB6F1 x C3D2F1 cross, the “non‐feminizing” estrogen, 17‐α‐estradiol (17aE2), extended median male lifespan by 19% (p < 0.0001, log‐rank test) and 1…”

Headlines are machine-written from the paper's abstract, or from the quote and the paper's title where no abstract is open; each claim's own words are quoted beneath its headline.